J B Chemicals &

Which are the latest news on J B Chemicals &?

How big is J B Chemicals &?

As of 10th June, J B Chemicals & Pharmaceuticals Ltd has a market capitalization of 35,628.00 Cr, with recent Net Sales of 4,147.79 Cr and a Net Profit of 709.46 Cr. Shareholder's Funds are 4,159.22 Cr and Total Assets are 4,961.77 Cr.

As of 10th June, J B Chemicals & Pharmaceuticals Ltd has a market capitalization of 35,628.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 4,147.79 Cr and a Net Profit of 709.46 Cr.<BR><BR>For the latest annual period ending March 2026, Shareholder's Funds amounted to 4,159.22 Cr, while Total Assets were reported at 4,961.77 Cr.

Why is J B Chemicals & Pharmaceuticals Ltd falling/rising?

As of 10-Jun, J B Chemicals & Pharmaceuticals Ltd's stock price is 2,203.70, reflecting a slight decline after three days of gains, but it has a strong year-to-date increase of 21.05%. Despite the recent drop in investor participation, the company maintains solid financial health with a high return on equity and significant institutional holdings.

As of 10-Jun, J B Chemicals & Pharmaceuticals Ltd is experiencing a slight decline in its stock price, currently at 2,203.70, reflecting a change of -6.15 (-0.28%). This drop comes after a period of three consecutive days of gains, indicating a potential trend reversal. Despite this short-term decline, the stock has shown strong performance over longer periods, with a year-to-date increase of 21.05% and a one-year increase of 32.28%, significantly outperforming the broader market, as evidenced by the Sensex's decline of 13.19% over the same period.<BR><BR>The stock's current price is also close to its 52-week high, being only 3.86% away from Rs 2,284.95. However, a notable factor contributing to the recent price drop is the decrease in investor participation, as indicated by a 29.93% decline in delivery volume compared to the five-day average. This reduced trading activity may reflect a temporary pullback in investor interest.<BR><BR>On a positive note, J B Chemicals & Pharmaceuticals Ltd maintains a high management efficiency with a return on equity (ROE) of 18.05% and a low debt-to-equity ratio of 0.02 times, suggesting strong financial health. Additionally, the company benefits from high institutional holdings at 37.72%, which often indicates confidence from more knowledgeable investors. Overall, while the stock is currently experiencing a decline, its long-term performance remains robust, supported by strong fundamentals.

What does J B Chemicals & do?

J B Chemicals & Pharmaceuticals Ltd manufactures and markets pharmaceutical formulations, herbal remedies, and Active Pharmaceutical Ingredients (APIs). As of March 2026, it reported net sales of ₹904 Cr and a net profit of ₹101 Cr, with a market cap of ₹35,628 Cr.

Overview: <BR>J B Chemicals & Pharmaceuticals Ltd is engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations, herbal remedies, and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History: <BR>The company was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 904 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 101 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 35,628 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 48.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.30% <BR>Debt Equity: -0.21 <BR>Return on Equity: 17.55% <BR>Price to Book: 8.52 <BR><BR>Contact Details: <BR>Address: Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli Mumbai Maharashtra : 400030 <BR>Tel: 91-022-2482 2222/2493 0918 <BR>Email: investorelations@jbcpl.com <BR>Website: http://www.jbpharma.com

Are J B Chemicals & Pharmaceuticals Ltd latest results good or bad?

J B Chemicals & Pharmaceuticals Ltd's latest Q4 FY26 results are concerning, with a net profit decline of 48.77% quarter-on-quarter and a 15.07% drop in net sales. Despite solid full-year growth for FY25, the sharp downturn in Q4 raises significant challenges for the company.

The latest results for J B Chemicals & Pharmaceuticals Ltd indicate a concerning performance in Q4 FY26. The company reported a net profit of ₹101.37 crore, which represents a significant decline of 48.77% quarter-on-quarter and 30.42% year-on-year. Similarly, net sales fell to ₹904.23 crore, down 15.07% from the previous quarter and 4.77% compared to the same quarter last year.<BR><BR>Additionally, the operating margin, excluding other income, decreased sharply to 22.24%, marking the lowest level for FY26 and a contraction of 558 basis points from the previous quarter. This decline in profitability and sales raises questions about the company's operational efficiency and pricing power.<BR><BR>While the full-year results for FY25 showed solid growth, with a 12.40% increase in net sales and a 19.38% rise in net profit, the sharp downturn in Q4 has overshadowed these achievements. Overall, the latest results suggest that J B Chemicals is facing significant challenges, making the current financial performance appear more negative than positive.

Should I buy, sell or hold J B Chemicals & Pharmaceuticals Ltd?

When is the next results date for J B Chemicals & Pharmaceuticals Ltd?

The next results date for J B Chemicals & Pharmaceuticals Ltd is 11 May 2026.

The next results date for J B Chemicals & Pharmaceuticals Ltd is scheduled for 11 May 2026.

How has been the historical performance of J B Chemicals &?

J B Chemicals & has shown consistent growth in net sales and profitability, with net sales increasing from 1,643.20 Cr in Mar'19 to 3,917.99 Cr in Mar'25, and profit after tax rising from 193.97 Cr to 659.58 Cr during the same period. The company also improved its operational efficiency and maintained a solid balance sheet, with total assets growing significantly.

Answer:<BR>The historical performance of J B Chemicals & shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>J B Chemicals & has demonstrated significant growth in net sales, increasing from 1,643.20 Cr in Mar'19 to 3,917.99 Cr in Mar'25. This upward trajectory reflects a robust annual growth rate, particularly notable from Mar'24 to Mar'25, where sales rose from 3,484.18 Cr to 3,917.99 Cr. The total operating income followed a similar pattern, reaching 3,917.99 Cr in Mar'25. Operating profit, excluding other income, also improved significantly, rising from 305.39 Cr in Mar'19 to 1,031.84 Cr in Mar'25, indicating enhanced operational efficiency. Profit before tax increased from 286.99 Cr in Mar'19 to 887.39 Cr in Mar'25, while profit after tax surged from 193.97 Cr to 659.58 Cr in the same period. The company's total assets grew from 1,813.98 Cr in Mar'20 to 4,265.36 Cr in Mar'25, reflecting a solid asset base. Total liabilities increased from 1,813.98 Cr to 4,265.36 Cr, with a notable reduction in long-term borrowings to zero by Mar'25. Cash flow from operating activities improved significantly, reaching 902.00 Cr in Mar'25, contributing to a closing cash balance of 115.00 Cr. Overall, J B Chemicals & has shown a strong upward trend in both revenue and profitability, alongside a solid balance sheet position.

Is J B Chemicals & technically bullish or bearish?

As of November 7, 2025, J B Chemicals & shows a mildly bullish trend driven by daily moving averages, despite caution from weekly and monthly indicators like MACD and KST, while volatility remains low according to Bollinger Bands.

As of 7 November 2025, the technical trend for J B Chemicals & has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly and monthly MACD and KST readings are mildly bearish, suggesting some caution. The RSI shows no signals in both weekly and monthly time frames, and Bollinger Bands are sideways, indicating a lack of volatility. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages, despite the bearish signals from other indicators.

Who are the top shareholders of the J B Chemicals &?

The top shareholders of J B Chemicals & include Tau Investment Holdings Pte. Ltd. with 47.84%, followed by 31 mutual fund schemes at 16.26%, 258 foreign institutional investors at 18.3%, and the Kotak Emerging Equity Scheme as the largest public shareholder at 4.25%. Individual investors collectively own 13.28% of the company.

The top shareholders of J B Chemicals & include several key players. The majority shareholder is Tau Investment Holdings Pte. Ltd., which holds 47.84% of the company. In addition, the company has a significant presence of institutional investors, with 31 mutual fund schemes holding a combined 16.26% and 258 foreign institutional investors (FIIs) owning 18.3%. The highest public shareholder is the Kotak Emerging Equity Scheme, which holds 4.25%. Individual investors collectively own 13.28% of the company.

Is J B Chemicals & overvalued or undervalued?

As of November 27, 2020, J B Chemicals & is considered very expensive and overvalued with a PE Ratio of 40.03 and an EV to EBITDA of 25.18, significantly higher than peers like Sun Pharma and Cipla, despite a recent return of 10.28% that underperformed the Sensex's 3.84%.

As of 27 November 2020, the valuation grade for J B Chemicals & has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 40.03, an EV to EBITDA of 25.18, and a PEG Ratio of 2.12, all of which are notably high compared to its peers.<BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla, which is rated as attractive, has a PE Ratio of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight that J B Chemicals & is trading at a premium relative to its peers. Additionally, while the stock has seen a return of 10.28% over the past month, it has underperformed the Sensex, which returned 3.84% in the same period, reinforcing the notion of overvaluation.

Who are in the management team of J B Chemicals &?

As of March 2023, the management team of J B Chemicals & includes Padmini Khare Kaicker, Sumit Bose, Ranjit Shahani, Prashant Kumar, Nikhil Chopra, Gaurav Trehan, and Sandeep Phadnis, who hold various roles such as directors and compliance officer.

As of March 2023, the management team of J B Chemicals & includes the following individuals:<BR><BR>1. Padmini Khare Kaicker - Non-Executive & Independent Director<BR>2. Sumit Bose - Non-Executive & Independent Director<BR>3. Ranjit Shahani - Chairman & Independent Director<BR>4. Prashant Kumar - Non-Executive & Non-Independent Director<BR>5. Nikhil Chopra - Whole Time Director & CEO<BR>6. Gaurav Trehan - Non-Executive & Non-Independent Director<BR>7. Sandeep Phadnis - Company Secretary & Compliance Officer<BR><BR>These individuals play various roles within the company's governance and management structure.

Has J B Chemicals & declared dividend?

J B Chemicals & Pharmaceuticals Ltd has declared an 850% dividend, amounting to ₹8.5 per share, with an ex-date of February 7, 2025. While recent short-term returns have been negative, the company has shown significant long-term growth, particularly with a total return of 404.05% over the past five years.

J B Chemicals & Pharmaceuticals Ltd has declared an 850% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 850%<BR>- Amount per share: 8.5<BR>- Ex-date: 07 Feb 2025<BR><BR>Dividend Yield: 0.9%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -2.78%, the dividend return was 0.48%, resulting in a total return of -2.3%.<BR><BR>For the 1-year period, the price return was -3.19%, the dividend return was 0.81%, leading to a total return of -2.38%.<BR><BR>Over the 2-year period, the price return was 61.46%, the dividend return was 2.56%, culminating in a total return of 64.02%.<BR><BR>In the 3-year period, the price return was 115.06%, the dividend return was 6.00%, resulting in a total return of 121.06%.<BR><BR>For the 4-year period, the price return was 126.48%, the dividend return was 7.68%, leading to a total return of 134.16%.<BR><BR>In the 5-year period, the price return was 383.78%, the dividend return was 20.27%, culminating in a total return of 404.05%.<BR><BR>Overall, J B Chemicals & Pharmaceuticals Ltd has declared a significant dividend, and while recent returns over shorter periods have been negative, the long-term performance shows substantial growth, particularly in price returns over the last five years.

Who are the peers of the J B Chemicals &?

J B Chemicals & peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Pfizer, Emcure Pharma, Wockhardt, OneSource Specialty, and ERIS Lifescience. Wockhardt has the highest 1-year return at 174.38%, while J B Chemicals & has a return of -4.32%.

Peers: The peers of J B Chemicals & are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Pfizer, Emcure Pharma, Wockhardt, OneSource Speci., and ERIS Lifescience.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, J B Chemicals &, Pfizer, Emcure Pharma, OneSource Speci., and ERIS Lifescience, while Average management risk is found at Wockhardt. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and OneSource Speci., while Average growth is noted for J B Chemicals & and Good growth is found at Wockhardt. Below Average growth is seen at Divi's Lab., Torrent Pharma, Pfizer, and Emcure Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.38%, while the lowest is Emcure Pharma, which has no available data. J B Chemicals & has a 1-year return of -4.32%, which is lower than both the highest and the lowest. Additionally, the six-month return is negative for J B Chemicals &, Sun Pharma.Inds., Torrent Pharma, and Emcure Pharma.